TORONTO, March 22, 2017 /CNW/ - Janssen Inc. welcomes the recognition of the health/bio-sciences industry in the 2017 Federal Budget as an economic driver and key area of investment in innovation. We look forward to working with the government to build on this recognition by engaging in meaningful and constructive dialogue about how the innovative life sciences sector can continue to contribute to the affordability and sustainability of our healthcare system for all Canadians. We believe life sciences should be central to Canada's innovation strategy.
In order for the sector to reach its full potential, we encourage government leadership to ensure the full health/bio-sciences ecosystem is supported from start-up innovators to commercialization. While the focus on superclusters, talent and scaling are positive steps, in order for Canada to achieve global leadership we must ensure that we have aligned and supportive policies through the ministries of health, innovation, economic development, finance, science and technology.
Our ability to invest in innovation in Canada is directly related to a supportive policy environment for the life sciences sector. Janssen is committed to the Canadian research community and our actions underscore this sentiment. Since 2014, we have committed more than $1 billion in a number of initiatives to contribute to and attract global life sciences investments to Canada.
We are committed to collaborating with government and all other relevant stakeholders to establish a strong research and innovation-based economy and ensure Canadians have access to the best possible healthcare now and in the future.
For more information, visit www.janssen.com/canada/about/innovation.
About Janssen Inc.Janssen Inc. is one of the Janssen Pharmaceutical Companies, which are dedicated to addressing and solving some of the most important unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world. Please visit www.janssen.com/canada for more information.
SOURCE Janssen Inc.
Advertisement
In order for the sector to reach its full potential, we encourage government leadership to ensure the full health/bio-sciences ecosystem is supported from start-up innovators to commercialization. While the focus on superclusters, talent and scaling are positive steps, in order for Canada to achieve global leadership we must ensure that we have aligned and supportive policies through the ministries of health, innovation, economic development, finance, science and technology.
Advertisement
Our ability to invest in innovation in Canada is directly related to a supportive policy environment for the life sciences sector. Janssen is committed to the Canadian research community and our actions underscore this sentiment. Since 2014, we have committed more than $1 billion in a number of initiatives to contribute to and attract global life sciences investments to Canada.
We are committed to collaborating with government and all other relevant stakeholders to establish a strong research and innovation-based economy and ensure Canadians have access to the best possible healthcare now and in the future.
For more information, visit www.janssen.com/canada/about/innovation.
About Janssen Inc.Janssen Inc. is one of the Janssen Pharmaceutical Companies, which are dedicated to addressing and solving some of the most important unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world. Please visit www.janssen.com/canada for more information.
SOURCE Janssen Inc.
